Crestwood Advisors Group LLC Buys Shares of 10,000 Monogram Orthopaedics Inc. $MGRM

Crestwood Advisors Group LLC bought a new stake in shares of Monogram Orthopaedics Inc. (NASDAQ:MGRM) in the 2nd quarter, according to its most recent filing with the SEC. The institutional investor bought 10,000 shares of the company’s stock, valued at approximately $29,000.

Separately, Focus Partners Advisor Solutions LLC raised its holdings in Monogram Orthopaedics by 6.1% in the first quarter. Focus Partners Advisor Solutions LLC now owns 213,678 shares of the company’s stock valued at $628,000 after acquiring an additional 12,328 shares in the last quarter. 0.45% of the stock is currently owned by institutional investors.

Monogram Orthopaedics Price Performance

Shares of MGRM opened at $6.00 on Friday. The stock has a market capitalization of $243.79 million, a PE ratio of -12.00 and a beta of 0.68. The business’s fifty day moving average price is $5.93 and its 200 day moving average price is $4.56. Monogram Orthopaedics Inc. has a 12-month low of $1.92 and a 12-month high of $6.43.

Monogram Orthopaedics (NASDAQ:MGRM) last issued its earnings results on Friday, August 15th. The company reported ($0.16) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.05). As a group, research analysts anticipate that Monogram Orthopaedics Inc. will post -0.49 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Separately, Weiss Ratings reissued a “sell (d-)” rating on shares of Monogram Orthopaedics in a report on Wednesday, October 8th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Monogram Orthopaedics currently has a consensus rating of “Moderate Buy” and an average target price of $5.40.

Monogram Orthopaedics Profile

Monogram Orthopaedics, Inc focuses on developing a product solution architecture to enable patient-optimized orthopaedic implants. The company intends to produce and market robotic surgical equipment and related software, orthopedic implants, tissue ablation tools, navigation consumables, and other miscellaneous instrumentation for use in reconstructive joint replacement procedures.